ライフサイエンスコーパス: all-cause mortality

1 idemiology and its impact on outcome (30-day all-cause mortality).

2 subsequent coronary heart disease, CVD, and all-cause mortality.

3 ssociated with a lower incidence of 12-month all-cause mortality.

4 Outcomes of interest were baseline HbA1c and all-cause mortality.

5 ater pectoralis muscle sarcopenia, and lower all-cause mortality.

6 The main outcome was 30-day all-cause mortality.

7 se at rates close to each country's rate for all-cause mortality.

8 volume) as independent predictors of 2-year all-cause mortality.

9 acute limb ischemia, revascularization, and all-cause mortality.

10 ngle end point for this interim analysis was all-cause mortality.

11 tions of dialysis vintage and NT-proBNP with all-cause mortality.

12 rction, stroke, and heart disease death, and all-cause mortality.

13 concentrations seemed to be associated with all-cause mortality.

14 The second coprimary outcome was 2-year all-cause mortality.

15 National registries captured all-cause mortality.

16 er investigated the effects of letermovir on all-cause mortality.

17 The main outcome was all-cause mortality.

18 talization, and 0.82 (95% CI, 0.80-0.83) for all-cause mortality.

19 curves were generated by treatment group for all-cause mortality.

20 iferous vegetables was associated with lower all-cause mortality.

21 ients with CRC in relation to recurrence and all-cause mortality.

22 antioxidant mixtures associated with reduced all-cause mortality.

23 The primary endpoint was all-cause mortality.

24 scular events (death or hospitalization) and all-cause mortality.

25 ssociate with an increased risk of long-term all-cause mortality.

26 xamined their longitudinal associations with all-cause mortality.

27 outcome and the kidney outcome, but not with all-cause mortality.

28 as a robust predictor of cardiovascular and all-cause mortality.

29 ty profile increased the prospective risk of all-cause mortality.

30 plement body mass index (BMI) when assessing all-cause mortality.

31 30-day cause-specific mortality, and 1-year all-cause mortality.

32 ffects of age on breast cancer incidence and all-cause mortality.

33 was not related to breast cancer-specific or all-cause mortality.

34 ther elevated FLI (>=60) was associated with all-cause mortality.

35 release exenatide, and dapagliflozin reduced all-cause mortality.

36 (3) progression to COPD at 5 years, and (4) all-cause mortality.

37 id (CSF) is used as a surrogate endpoint for all-cause mortality.

38 17-3.76]) were significantly associated with all-cause mortality.

39 nary revascularization), and in Medicare for all-cause mortality.

40 s were the ICU length of stay and the 28-day all-cause mortality.

41 teps was significantly associated with lower all-cause mortality.

42 quality of life, target limb amputation, and all-cause mortality.

43 farin and DOACs were associated with reduced all-cause mortality.

44 alone or antioxidants was seen with CVD and all-cause mortality.

45 ar disease and Alzheimer disease, as well as all-cause mortality.

46 ildhood cancer survivors and associated with all-cause mortality.

47 dividual and composite end points, including all-cause mortality.

48 tus, including a 3-fold greater reduction in all-cause mortality.

49 ciated with cardiovascular disease (CVD) and all-cause mortality.

50 initiated after breast cancer diagnosis and all-cause mortality.

51 cations on incident heart failure events and all-cause mortality.

52 edicted accumulation of chronic diseases and all-cause mortality.

53 ed these endpoints individually and assessed all-cause mortality.

54 azard ratio was 0.75 (95% CI, 0.74-0.76) for all-cause mortality, 0.80 (95% CI, 0.78-0.81) for cardio

55 ted were independent predictors of increased all-cause mortality: 1-year actuarial survival was 86 +/

56 to 2.84%) for the background population; and all-cause mortality: 10.88% (95% CI: 10.23% to 11.55%) f

57 CIED infection was associated with increased all-cause mortality (12-month risk-adjusted hazard ratio

58 s associated with decreased adjusted risk of all-cause mortality (13 studies, n = 36 986; pooled haza

59 76), a nonsignificant decrease in short-term all-cause mortality (2.6% vs. 3.9%, AOR, 0.79; 95% CI, 0

60 1% [95% CI, -0.4% to 0.6%]; P = .82); and of all-cause mortality, 22.4% vs 23.5% (difference, 1.1% [9

61 r the individual components were as follows: all-cause mortality, 3.2% versus 2.3% (rate difference,

62 ng events (3.8% vs. 0.8%; p = 0.011), 2-year all-cause mortality (40.5% vs. 18.7%; p <0.001), and maj

63 cedure conferred even worst outcomes (2-year all-cause mortality 50.0% vs. 19.6%; p = 0.001, and majo

64 08), and a significant decrease in long-term all-cause mortality (51% vs. 58%, AOR, 0.87; 95% CI, 0.8

65 dence interval: 0.68 to 0.88; p < 0.001) and all-cause-mortality (7.6% vs. 9.7%; adjusted hazard rati

66 ace-specific analysis, the PAFs of NAFLD for all-cause mortality (9.3%; 95% CI, 4.0, 14.6) and diabet

67 ; HR, 0.63 [95% CI, 0.43-0.93]; P=0.02), and all-cause mortality (9.8% to 7.2%; HR, 0.70 [95% CI, 0.5

68 or CVDM (95% CI, 1.03 to 1.49), and 1.23 for all-cause mortality (95% CI, 1.11 to 1.35).

69 ratios for coronary heart disease, CVD, and all-cause mortality according to categories of BMI and C

70 ssed clinical response at day 14, and 30-day all-cause mortality (ACM) (secondary endpoints), and tim

71 However, reductions in all-cause mortality (ACM) are harder to demonstrate.

72 rial demonstrated a significant reduction in all-cause mortality (ACM) risk with fluticasone furoate/

73 factor for cardiovascular events (CVEs) and all-cause mortality (ACM), but data at earlier stages of

74 yocardial infarction or nonfatal stroke, and all-cause mortality (ACM), given that some of these agen

75 with long-term (median follow-up 4.7 years) all-cause mortality (adjusted hazard ratio, 1.93 [95% CI

76 was associated with an ~8-fold reduction in all-cause mortality (adjusted hazard ratio: 0.12; p = 0.

77 f BBxgenotype interaction predicting time to all-cause mortality, adjusted for Meta-Analysis Global G

78 1MI, patients with T2MI had higher long-term all-cause mortality after adjustment for age and sex, dr

79 tudy aimed to investigate the association of all-cause mortality after percutaneous coronary interven

80 sed adjusted hazard ratio (aHR) for MACCE or all-cause mortality (aHR, 1.71 [1.13-2.60]; P = 0.012) e

81 DBP, and RHR were univariable predictors of all-cause mortality (all p <= 0.002).

82 lly enrolled beneficiaries had higher annual all-cause mortality, all-cause hospitalizations, and hos

83 The primary outcomes were 1-year all-cause mortality, all-cause readmission, and the comp

84 ociated with lower rates of the composite of all-cause mortality, all-cause stroke, myocardial infarc

85 We found the lowest HR of all-cause mortality among overweight individuals with hi

86 moke exposure was positively associated with all-cause mortality among patients receiving in-center h

87 ld be strengthened to decrease TB burden and all-cause mortality among PLHIV with presumptive TB.

88 Secondary end points included all-cause mortality and all major vascular events (cardi

89 in amyloid cardiomyopathy, tafamidis reduces all-cause mortality and cardiovascular hospitalizations

90 nt comparisons may be valid and feasible for all-cause mortality and certain procedural outcomes but

91 2%, 97%; p < 0.001) higher than expected for all-cause mortality and CVD mortality, respectively, und

92 We estimated hazard ratios for all-cause mortality and deaths from cardiovascular disea

93 he accuracy of these mediators in predicting all-cause mortality and examined whether markers could i

94 Primary clinical outcomes were all-cause mortality and heart failure-related hospitaliz

95 in and direct oral anticoagulants (DOACs) on all-cause mortality and hepatic decompensation as well a

96 was associated with the lowest incidence of all-cause mortality and HF hospitalization.

97 association of follow-up testing with 30-day all-cause mortality and hospitalization with acute kidne

98 Patients with hypertension have increased all-cause mortality and infection-related mortality duri

99 r-to-needle times were associated with lower all-cause mortality and lower all-cause readmission at 1

100 LA, proxy for vegetable omega-3 intake) with all-cause mortality and MACE.

101 relationships between malnutrition risk and all-cause mortality and major cardiovascular events (MAC

102 reasingly important; this study investigated all-cause mortality and morbidity outcomes of LD compare

103 In the United States, approximately 8% of all-cause mortality and more than one-third of LD- and d

104 nitial infection, fate of primary infection, all-cause mortality and mortality secondary to coccidioi

105 udy investigated the association of UMI with all-cause mortality and nonfatal MI (death and/or MI), a

106 The association between all-cause mortality and routinely measured DBP and RHR w

107 ationship between handgun ownership and both all-cause mortality and suicide (by firearm and by other

108 All-cause mortality and the composite of myocardial infa

109 rmed bariatric or metabolic surgery) reduces all-cause mortality and the development of obesity-relat

110 overt hematologic malignancy, and increases all-cause mortality and the risk of cardiovascular disea

111 Results were similar for all-cause mortality and with varying PMI(UD) biomarker d

112 composite clinical failure defined as 60-day all-cause mortality and/or 60-day recurrence compared wi

113 tcome was composite clinical failure (60-day all-cause mortality and/or 60-day recurrence).

114 cardiac and cerebrovascular event [MACCE] or all-cause mortality) and secondary (MACCE or cardiovascu

115 edian time to oral antibiotic stepdown, LOS, all-cause mortality, and incidence of AKI and CDI.

116 and adverse pregnancy outcomes, maternal TB, all-cause mortality, and liver injury during pregnancy t

117 le outcomes (composite of treatment failure, all-cause mortality, and recurrence), and individual out

118 d for the components of the primary outcome, all-cause mortality, and symptoms.

119 The primary outcome was all-cause mortality, and the secondary outcome was cause

120 Secondary endpoints: clinical response, all-cause mortality, and treatment-emergent nephrotoxici

121 ted quality of life at 30, 90, and 180 days; all-cause mortality; and percentage of opacification on

122 osite end point, defined as the composite of all-cause mortality, any myocardial infarction, or any r

123 The overall PAF for all-cause mortality associated with NAFLD was 7.5% (95%

124 Primary outcomes were all-cause mortality at 1 and 2 years, and secondary outc

125 an FFR-guided revascularization strategy and all-cause mortality at 1 year.

126 , their clinically relevant association with all-cause mortality at 10 years, and their impact on com

127 Secondary outcomes were all-cause mortality at 28 days, clinical status of patie

128 ce in the prespecified secondary outcomes of all-cause mortality at 28 days, ICU-free days during the

129 Primary end point was all-cause mortality at 3 years follow-up.

130 OAF was associated with a 3-fold increase in all-cause mortality at 30 days (weighted mean, 15.0% ver

131 The primary outcome was all-cause mortality at 6 months, assessed in the intenti

132 intensive care unit and hospital stays, and all-cause mortality at postoperative days 28 and 90.

133 We found no difference in all-cause mortality at the longest follow-up available (

134 , 12 CpGs were significantly associated with all-cause mortality (Bonferroni corrected P<1.6x10(-3)).

135 s) have demonstrated that BCG-Denmark lowers all-cause mortality, but a recent RCT found no effect of

136 ns were associated with an increased risk of all-cause mortality, but not of CVD.

137 rAg) combined with adherence support reduced all-cause mortality by 28%, compared with standard clini

138 Unadjusted incidence density for all-cause mortality by peak 30 cadence was 32.9 per 1000

139 Outcomes were all-cause mortality, cause of death, relapse, recurrence

140 duced 2-year rates of HF hospitalization and all-cause mortality compared with GDMT alone.

141 loquinone had an adjusted 19% higher risk of all-cause mortality compared with those with >1.0 nmol/L

142 ry outcomes were admission haematoma volume, all-cause mortality, death or major disability (modified

143 Although all-cause mortality decreased 16.4% across all ages, mor

144 isability-free survival," was a composite of all-cause mortality, dementia, or persistent physical di

145 e primary safety endpoint was a composite of all-cause mortality, disabling stroke, life-threatening

146 The impact of frailty on all-cause mortality during 6 years of follow-up and inci

147 cemaker dependency at 30 days and 1 year and all-cause mortality during follow-up were evaluated.

148 ata, daily ambient apparent temperature, and all-cause mortality during May-September, 2000-2009.

149 btained within 72 hours of presentation, and all-cause mortality (during hospitalization, at 30-days

150 ischarge was associated with a lower rate of all-cause mortality, especially among patients receiving

151 7.4%, and 5.2% of the total effect of PA on all-cause mortality, fatal CVD, and nonfatal CVD events,

152 to investigate associations of PA level with all-cause mortality, fatal CVD, and nonfatal CVD events.

153 in Ontario, Canada, we estimated VE against all-cause mortality following laboratory-confirmed influ

154 variable adjustment, we estimated VE against all-cause mortality following laboratory-confirmed influ

155 base for potential CVD outcomes, cancer, and all-cause mortality following selenium supplementation a

156 y prevalence (2001-16) and relative risks of all-cause mortality for 168 countries.

157 r PAEE was associated with a lower hazard of all-cause mortality for a constant fraction of MVPA (for

158 ty markers including survival analysis using all-cause mortality from diagnosis.

159 t an important future clinical event, 1-year all-cause mortality, from ECG voltage-time traces.

160 For each risk factor, estimated all-cause mortality hazard ratios (HR) and population at

161 of 5 kg/m(2) was associated with 29% higher all-cause mortality (hazard ratio (HR) = 1.29, 95% confi

162 tile) was associated with increased risks of all-cause mortality (hazard ratio (HR) = 1.36, 95% confi

163 ariate Cox regression analysis showed higher all-cause mortality (hazard ratio 3.8; P = .01) with pro

164 fuel users had significantly higher risks of all-cause mortality (hazard ratio [HR] 1.19, 95% CI 1.10

165 HF readmission did not significantly impact all-cause mortality (hazard ratio [HR], 1.36 [95% CI, 0.

166 models, PN was significantly associated with all-cause mortality (hazard ratio [HR], 1.49 [CI, 1.15 t

167 All-cause mortality (hazard ratio [HR]: 1.39; 95% CI: 1.

168 .005, respectively, P(interaction)=0.77) and all-cause mortality (hazard ratio, 0.81, P=0.05; and haz

169 ths in late adulthood had increased risks of all-cause mortality (hazard ratio, 1.16 [95% CI, 1.01-1.

170 group had lower adjusted risk estimates for all-cause mortality (hazard ratio: 0.81; 95% confidence

171 endpoint was a composite safety endpoint of all-cause mortality, heart failure-related hospitalizati

172 n LGE and the composite primary end point of all-cause mortality, heart transplantation, or left vent

173 improve quality of life but will also reduce all-cause mortality, hospital admissions and lifetime he

174 CB (DHP-CCB) use was associated with reduced all-cause mortality (HR 0.67, 95%CI: 0.45-0.98) only by

175 datasets and it is strongly associated with all-cause mortality (HR 1.18 per point increase in score

176 tcome (HR for LAEDVI, 2.97; P<0.001) and for all-cause mortality (HR for LAEDVI, 2.08; P<0.001).

177 seline global efficiency was associated with all-cause mortality (HR per decrease of 1 SD 0.43, 95% C

178 day was associated with significantly lower all-cause mortality (HR, 0.49 [95% CI, 0.44-0.55]), as w

179 d points (hazard ratio [HR], 0.60; P=0.006), all-cause mortality (HR, 0.54; P=0.019), and cardiovascu

180 farction (HR, 0.71 [95% CI, 0.51-1.003]) and all-cause mortality (HR, 0.68 [95% CI, 0.40-1.14]) but n

181 lower adjusted hazard ratio (HR) of overall all-cause mortality (HR, 0.68 [95% CI, 0.57 to 0.81]).

182 rd ratio [HR], 0.82 [95% CI, 0.72-0.92]) and all-cause mortality (HR, 0.83 [95% CI, 0.75-0.92]), wher

183 abetes, PN was significantly associated with all-cause mortality (HR, 1.31 [CI, 1.15 to 1.50]), but t

184 n average FHS user had a 44% lower hazard of all-cause mortality (HR: 0.56, 95% CI 0.54-0.59, p < 0.0

185 Serum-PC ALA was inversely related to all-cause mortality (HR: 0.65; 95% CI: 0.44 to 0.96, for

186 Rs were significantly associated with higher all-cause mortality in both sexes combined.

187 short term risk period were associated with all-cause mortality in Cox proportional hazard model (OR

188 onal hazards models, we found a reduction in all-cause mortality in de novo vitamin D users compared

189 s (CIs) were calculated for transplant-free, all-cause mortality in Hispanic patients with non-Hispan

190 An elevated FLI (>=60) is a risk factor for all-cause mortality in HIV-HCV-coinfected patients indep

191 These cPRS were moderately associated with all-cause mortality in independent data within the UK Bi

192 was not significantly associated with 30-day all-cause mortality in Kaiser Permanente Northern Califo

193 The relative risks (95%CI) of all-cause mortality in males vs. females with T2DM aged

194 increase in coronary heart disease, CVD, and all-cause mortality in obese individuals appeared largel

195 imited to men, and there was a lower risk of all-cause mortality in overweight women (hazard ratio, 0

196 ciated with a similar increase in subsequent all-cause mortality in participants treated with or with

197 the association between IL-1beta level with all-cause mortality in patients with acute ST-segment el

198 estigate the association of DBP and RHR with all-cause mortality in patients with AR.

199 The HR for all-cause mortality in patients with CS-CMVi was 0.45 (9

200 ater BB exposure was associated with reduced all-cause mortality in patients with low PRP score (n=25

201 thresholds for reduction in risk of MACE and all-cause mortality in patients with obesity and diabete

202 symptoms, comorbidities, and determinants of all-cause mortality in patients with severe calcific MS.

203 nd magnesium, we observed the lowest risk of all-cause mortality in patients with sufficient vitamin

204 ell count at ART initiation, rates of excess all-cause mortality in people with history of mental ill

205 ify variable DNA methylation associated with all-cause mortality in smokers with and without COPD.

206 inations of conditions), baseline HbA1c, and all-cause mortality in T2D.

207 NT-proBNP was independently associated with all-cause mortality in the fully adjusted model (HR, 1.3

208 sted association of knee osteoarthritis with all-cause mortality in the MOA sample had a hazard ratio

209 The primary endpoint was day 28 all-cause mortality in the modified intent-to-treat (MIT

210 omodulin did not significantly reduce 28-day all-cause mortality in the Sepsis Coagulopathy Asahi Rec

211 HR, 0.70 [95% CI, 0.55-0.90]; P=0.004); for all-cause mortality in the US versus non-US patients, P(

212 ity modifies the association between BMI and all-cause mortality in women and men.

213 The lower risk for MI, CHD, and all-cause mortality in women versus men is considerably

214 es to be associated with CKD progression and all-cause mortality, independent of eGFR and albuminuria

215 patients hospitalized with HF and predicted all-cause mortality independently of LVEF.

216 change) and sex and the composite outcome of all-cause mortality, LV assist device implantation, or h

217 These included risks of subsequent 5-year all-cause mortality, major adverse cardiovascular events

218 ization), heart failure hospitalization, and all-cause mortality (Medicare only) in the 365 days afte

219 egression to characterize temporal trends in all-cause mortality, mortality resulting directly attrib

220 e cardiovascular events (MACE) (composite of all-cause mortality, myocardial infarction, stroke, or e

221 ospitalization or death from HF; n=191), and all-cause mortality (n=527; 3-year median follow-up afte

222 rebrovascular events (MACCE), a composite of all-cause mortality, non-procedural myocardial infarctio

223 Secondary endpoints included all-cause mortality, non-procedural myocardial infarctio

224 brovascular events ([MACCE] the composite of all-cause mortality, nonfatal myocardial infarction, and

225 the rate of the trial's primary end point of all-cause mortality occurred in 13.7% of patients receiv

226 Ninety-day all-cause mortality occurred in 150 of 300 patients vs 1

227 The 30-day all-cause mortality occurred in 4.9% (107 of 2,191) and

228 oderate- or high-quality evidence of reduced all-cause mortality (odds ratio [OR], 0.56; 95% confiden

229 Assessment of all-cause mortality of intracerebral hemorrhage and isch

230 d population attributable fraction (PAF) for all-cause mortality of presentation to care with advance

231 ire PM(2.5) associated with a 4% increase in all-cause mortality on the same day (RR, 1.04; 95% confi

232 and Ang II peptide levels failed to predict all-cause mortality or hospitalization duration in our p

233 f poor MH and plasma biomarkers with time-to-all-cause mortality or incident myocardial infarction.

234 uction of the primary composite end point of all-cause mortality or new Q-wave myocardial infarction.

235 0.85 [95% CI, 0.80-0.89]), and composite of all-cause mortality or readmission (56.0% versus 58.4%;

236 all-cause readmission, and the composite of all-cause mortality or readmission.

237 We found no racial/ethnic disparities in all-cause mortality or use of cardiovascular disease pro

238 ty or death (OR, 1.05; 95% CI 0.61 to 1.63), all-cause mortality (OR, 0.89; 95% CI 0.47 to 1.85), adm

239 The primary endpoint was all-cause mortality, or discharge from hospital, as asse

240 , major bleeding, myocardial infarction, and all-cause mortality over 2 years of follow-up were inves

241 nce of FMR was independently associated with all-cause mortality (p <= 0.004).

242 Patients with CS-CMVi had higher all-cause mortality (P = .007), especially those with lo

243 sociated CpGs were nominally associated with all-cause mortality (P<0.05).

244 ), myocardial infarction (P(trend)=0.65), or all-cause mortality (P(trend)=0.89).

245 P(interaction)<0.0001; 1.9% versus 0.6% for all-cause mortality, P(interaction)=0.02; 2.7% versus 1.

246 intention-to-treat analysis was followed for all-cause mortality; participants diagnosed with or rece

247 rse cardiac events defined as a composite of all-cause mortality, periprocedural myocardial infarctio

248 s inflammatory subtype of NAFLD, with annual all-cause mortality rate of 25.56 per 1000 person-years

249 All-cause mortality rates at 30, 90, and 365 days were s

250 lished meta-analysis; population numbers and all-cause mortality rates from the Human Mortality Datab

251 Thirty-day all-cause mortality rates were 9.7% and 12.8% in the exe

252 s of dual versus triple therapy on risks for all-cause mortality (RD, 0.004 [CI, -0.010 to 0.017]), c

253 This group had a 4.54 times higher all-cause mortality risk (95% CI 4.07-5.06) than that of

254 regression model was fitted to ascertain the all-cause mortality risk associated with each cluster.

255 To quantify and compare 9-year all-cause mortality risk attributable to modifiable risk

256 eeded to elucidate the findings of increased all-cause mortality risk in patients receiving basal ins

257 ower lobe cancer is associated with a higher all-cause mortality risk in patients with NSCLC, which i

258 es if they are to be associated with CVD and all-cause mortality risk reduction.

259 Use of ventilation was associated with lower all-cause mortality risk, even among persistent clean fu

260 Compared with never-smokers, the all-cause mortality RR was highest in participants who h

261 idant mixture, a decreased risk was seen for all-cause mortality (RR: 0.90; 95% CI: 0.82, 0.98; P = 0

262 Primary outcomes included all-cause mortality, severe necrotizing enterocolitis (N

263 All-cause mortality showed a J-shaped association with B

264 Secondary outcomes included all-cause mortality, stroke, and rehospitalization at 1

265 objective of this study was to describe the all-cause mortality, TB incidence rates and their associ

266 green cluster was positively associated with all-cause mortality (tertile 3 vs. tertile 1: hazard rat

267 es naeslundii) was inversely associated with all-cause mortality (tertile 3 vs. tertile 1: HR = 0.65,

268 orange cluster was inversely associated with all-cause mortality (tertile 3 vs. tertile 1: HR = 0.78,

269 %), and they had significantly higher 2-year all-cause mortality than those with 1 or none of these m

270 For all-cause mortality, the threshold for benefit appeared

271 Incidence of all-cause mortality through week 48 post-HCT in the lete

272 f parenteral anticoagulant administration on all-cause mortality, venous thromboembolism occurrence,

273 GLS value at which the hazard ratio (HR) for all-cause mortality was >1 using a spline curve analysis

274 Following letermovir prophylaxis, the HR for all-cause mortality was 0.58 (95% CI, 0.35-0.98; P = .04

275 At 1 year, all-cause mortality was 10.2% (117 patients) in the drug

276 cillin/tazobactam for both endpoints: day 28 all-cause mortality was 15.9% with imipenem/cilastatin/r

277 All-cause mortality was 2.9% in the intervention group a

278 The 1-year all-cause mortality was 36.7% (95% CI, 36.1-7.4) for all

279 e SMR compared to the general population for all-cause mortality was 5.9 (95% CI 5.5-6.2) and among 5

280 The unadjusted incidence density for all-cause mortality was 76.7 per 1000 person-years (419

281 All-cause mortality was estimated in 9% after PCI versus

282 6 to 12 months, no significant difference in all-cause mortality was found, however, with numerically

283 All-cause mortality was increased in women (hazard ratio

284 5-year risk of first-time CVA, MI, CHF, and all-cause mortality was investigated using multivariate

285 All-cause mortality was lower with warfarin versus no AC

286 ically developed cities in China, the lowest all-cause mortality was observed for a BMI of 22.5 kg/m(

287 All-cause mortality was significant lower in the ICD gro

288 The 30-day all-cause mortality was significantly higher in patients

289 er 3 years of follow-up (n = 1,775, 9 RCTs), all-cause mortality was significantly lower in the DCB g

290 unit, mechanical ventilation, or in-hospital all-cause mortality) was comparable between SOTr and con

291 HRs for all-cause mortality were 0.86 (95% confidence interval:

292 re and low alcohol intake, HRs (95% CIs) for all-cause mortality were 0.93 (0.89, 0.97; p = 0.001), 1

293 y.The hazard ratios for critical disease and all-cause mortality were 7.2 (95% CI 3.0-17) and 8.6 (95

294 Incident CVD and all-cause mortality were identified using national regis

295 between calcium and vitamin D in relation to all-cause mortality were observed.

296 Rates of HF readmissions and all-cause mortality were then compared between the all H

297 The primary outcome was all-cause mortality, with cause-specific mortality as th

298 italization, reinitiation of antibiotics, or all-cause mortality within 30 days of antibiotic complet

299 The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID

300 The primary outcome was all-cause mortality within 90 days during index hospital